Moteur de recherche d’entreprises européennes
Financement de l’UE (2 532 975 €) : Immunothérapie immunosélective et immunothérapeutique sélective contre le cancer Hor13/11/2018 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Immunothérapie immunosélective et immunothérapeutique sélective contre le cancer
I-DireCT is a European Industrial Doctorate (EID) training network designed to provide training and carry out breakthrough research on the rapidly expanding and high impact field of cancer immunotherapy in a carefully integrated academic and inter-sectoral programme. Hereby, we aim to develop next-generation immunotherapeutics and deliver a set of early stage researchers uniquely qualified for a career in academia and/or industry. Current immunomodulatory antibodies that target pivotal immune checkpoints have revolutionized the field of oncology. However, off-tumor activity limits their application. The objective of I-Direct is to address this issue by 1. developing innovative bispecific antibodies and immunocytokines with tumor-restricted immunostimulatory effects and 2. developing optimized delivery systems to ensure optimal timed release of bio-active drug. Hereto, I-DireCT combines state-of-the-art industrial design of nanotech-based drug formulations with innovative academic and industrial immunotherapeutic concepts into the next-generation of cancer immunotherapeutics. At the core of I-DireCT is its training objective to offer a cutting-edge multidisciplinary training programme that will enable outstanding young scientists to generate breakthrough ideas and assume leading positions in academia and industry. This training programme includes an array of disciplines, ranging from biomedical sciences (e.g. immunology, antibody engineering) and physical sciences (e.g. chemistry, material science) to drug design & development. Industrial partners are central to the programme and provide pivotal inter-sectoral expertise on how to translate scientific discoveries into commercial reality, with each ESR being appointed at an inter-sectoral partner for 18 months, as well as through additional secondments. Further, I-Direct will enable long-term multi-disciplinary research and fosters bilateral co-operations between academia and industry.
| ACADEMISCH ZIEKENHUIS GRONINGEN | 922 291 € |
| Inocure s.r.o. | 469 743 € |
| KAHR MEDICAL Ltd. | 256 181 € |
| Surflay Nanotec GmbH | 505 577 € |
| UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT | 379 183 € |
https://cordis.europa.eu/project/id/813871
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "ACADEMISCH ZIEKENHUIS GRONINGEN - Financement de l’UE (2 532 975 €) : Immunothérapie immunosélective et immunothérapeutique sélective contre le cancer"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
